Hemophilia A is a blood disorder where people don’t have enough of a protein called Factor VIII (FVIII), which helps blood clot. Without enough FVIII, people can bleed a lot, even from small injuries. Some people develop inhibitors, which are like blockers that stop FVIII treatments from working. This study looks at ways to help people with Hemophilia A who have these inhibitors.

This study is non-interventional, meaning it does not involve testing new drugs, but observes existing treatments. The goal is to see how effective and safe different treatments are. It focuses on immune tolerance induction (ITI), a method to remove inhibitors. Participants are followed for up to 5 years and divided into three groups based on their treatment plan. Treatments involve FVIII, a new medicine called emicizumab, and other special medicines for bleeding.

• The study lasts up to 5 years.
• The study is done at multiple locations worldwide.
• Participants will be in one of three treatment groups.